Alfatradiol
Alfatradiol (17-alpha-estradiol) is a topical epimer of estradiol used for androgenetic alopecia. It inhibits 5-alpha-reductase locally in the scalp while carrying only weak systemic estrogenic activity, making it a milder alternative to finasteride for people wary of systemic anti-androgen effects.
01 Overview
Marketed in Europe as Ell-Cranell alpha and Pantostin, alfatradiol is applied as a scalp solution to slow hair loss. Its appeal is topical action with minimal feminising potential compared to oral 5ARIs, though the trade-off is more modest efficacy.
Evidence is limited to a handful of controlled trials, most showing stabilisation rather than robust regrowth. It is often chosen by men who fear post-finasteride syndrome or by women where systemic anti-androgens are undesirable.
02 Mechanism
Locally inhibits 5-alpha-reductase in the hair follicle, reducing conversion of testosterone to dihydrotestosterone (DHT) at the scalp. The 17-alpha configuration greatly weakens estrogen-receptor binding versus estradiol.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Standard | 0.025 %/day | Transdermal | 3 mL of 0.025% solution to the scalp once daily |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Slowed hair lossReduces the rate of miniaturisation, typically halting shedding rather than producing dense regrowth. | Stabilisation in most responders | Clinical | |
| Local DHT reductionLowers follicular DHT while sparing serum DHT compared with oral 5ARIs. | Scalp-localised | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Scalp irritationItching, redness or dryness at the application site. | Mild | Common | Clinical | |
| Weak systemic estrogenic effectTheoretical low-level estrogenic activity with high-dose or occlusive use. | Mild | Rare | Preclinical |